The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction.

Autor: Stass H; BAYER HealthCare AG, Research Center, Wuppertal, Germany., Bührmann S, Mitchell A, Kubitza D, Möller JG, Kribben A, Wenzel RR, Schäfers RF
Jazyk: angličtina
Zdroj: British journal of clinical pharmacology [Br J Clin Pharmacol] 2007 Dec; Vol. 64 (6), pp. 745-9. Date of Electronic Publication: 2007 Jun 06.
DOI: 10.1111/j.1365-2125.2007.02902.x
Abstrakt: Aim: We investigated single dose and steady-state pharmacokinetics of moxifloxacin in eight venovenous haemodialysis patients.
Methods: Plasma, dialysate and urine pharmacokinetic parameters for moxifloxacin and its main metabolites were calculated after single and multiple (7 days) dosing with 400 mg day(-1).
Results: Moxifloxacin pharmacokinetics after a single dose and at steady state (multidose day 7) were comparable in patients with impaired renal function and healthy subjects (geometric mean/%CV AUC mg l(-1) h single dose 37.0/24.3 in haemodialysis patients vs. 29.8/22.6 in healthy subjects, 95% CI for ratio of haemodialysis patients to healthy subjects 99.34%, 154.60%; steady state 40.4/29.1 haemodialysis patients vs. 33.9/20.1 in healthy subjects, 95% CI for ratio of haemodialysis patients to healthy subjects 90/39%, 156.93%). In haemodialysis patients plasma concentrations of moxifloxacin at steady-state were elevated compared with those after a single 400 mg dose (AUC mg l(-1) h, geometric mean/%CV, 40.4/29.1) compared with 37.0/24.3; 95% CI for ratio of steady-state to single dose 87.29%, 136.52%, as were concentrations of metabolite M1 3.21/34.6 compared with 2.02/45.3, 95% CI for ratio of steady state to single dose 14.21%, 175.07%. Haemodialysis cleared about 9% of the dose as unchanged moxifloxacin.
Conclusions: No dose adjustments are required for venovenous haemodialysis patients on oral moxifloxacin therapy.
Databáze: MEDLINE
Externí odkaz: